SCHEMBL222049

SCHEMBL222049

C[C@@](N)(C(=O)O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.58
CYP2C19 P33261 3/20 0.58
MAPT P10636 1/20 0.56
KMT2A Q03164 1/20 0.56
CYP2D6 P10635 2/20 0.55
HIF1A Q16665 2/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
KCNN4 O15554 2/20 0.46
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220775 1.00 CYP1A2 (0.58) CYP1A2CYP2C19MAPTKMT2ACYP2D6
SCHEMBL59841 1.00 CYP1A2 (0.58) CYP1A2CYP2C19MAPTKMT2ACYP2D6
Methyl Alcohol SCHEMBL29003577 0.98 CYP1A2 (0.56) CYP1A2CYP2C19MAPTKMT2ACYP2D6
Hydrochloric Acid SCHEMBL6369027 0.98 CYP1A2 (0.56) CYP1A2CYP2C19MAPTKMT2ACYP2D6
Hydrochloric Acid SCHEMBL304449 0.98 CYP1A2 (0.56) CYP1A2CYP2C19MAPTKMT2ACYP2D6
Hydrochloric Acid SCHEMBL1455022 0.98 CYP1A2 (0.56) CYP1A2CYP2C19MAPTKMT2ACYP2D6
SCHEMBL30577995 0.90 CYP1A2 (0.50) CYP1A2CYP2C19MAPTKMT2ACYP2D6
SCHEMBL5565841 0.90 CYP1A2 (0.54) CYP1A2CYP2C19MAPTKMT2ACYP2D6
SCHEMBL7384716 0.87 CYP2C9 (0.57) CYP1A2CYP2C19MAPTKMT2ACYP2D6
SCHEMBL18209210 0.87 CYP1A2 (0.47) CYP1A2CYP2C19MAPTKMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6759551-B1 COMPOUND IS DISSOLVED, IN THE FREE AMINO ACID FORM OR IN THE SALIFIED FORM, IN A PH REGION OF LESS THAN APPROXIMATELY 4.5 OR GREATER THAN APPROXIMATELY 9, THEN PH IS GRADUALLY BROUGHT, BY ADDITION OF A BASE OR OF AN ACID RESPECTIVELY, TO NEUTRAL BAYER CROPSCIENCE S.A. (FR) 2004-07-06 US claimed
US-6570021-B2 For producing fungicidal 2-imidazolin-5-one compounds RHONE-POULENC AGRO (FR) 2003-05-27 US claimed
EP-1226111-A1 CHIRAL (S- OR R-METHYLPHENYLGLYCINE) AMINO ACID CRYSTAL AND METHOD FOR PREPARING SAME AVENTIS CROPSCIENCE S.A. (FR) 2002-07-31 EP claimed
US-20020038034-A1 Intermediates for the preparation of 2-imidazolin-5-ones BUFORN ALBERT (FR) 2002-03-28 US claimed
WO-2001032603-A1 CHIRAL (S- OR R-METHYLPHENYLGLYCINE) AMINO ACID CRYSTAL AND METHOD FOR PREPARING SAME AVENTIS CROPSCIENCE S.A (FR) 2001-05-10 WO claimed
US-4714696-A Novel derivatives of arginine vasopressin antagonists MEDICAL COLLEGE OF OHIO (US) 1987-12-22 US claimed
EP-0061356-A2 Antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin Medical College of Ohio (US) 1982-09-29 EP claimed
US-20250011333-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2025-01-09 US disclosed
US-11814444-B2 Cyclic polypeptides for PCSK9 inhibition RA PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS Nerviano Medical Sciences, S.R.L. (IT) 2021-09-30 US disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 US disclosed
EP-2838900-B1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2019-08-21 EP disclosed
US-10344019-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2019-07-09 US disclosed
US-5352788-A Angiotensin antagonist ELF SANOFI (FR) 1994-10-04 US disclosed
WO-1994001410-A1 FUNGICIDAL 2-IMIDAZOLINE-5-ONE AND 2-IMIDAZOLINE-5-THIONE DERIVATIVES RHONE POULENC AGROCHIMIE (FR) 1994-01-20 WO disclosed
US-5270317-A N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present ELF SANOFI (FR) 1993-12-14 US disclosed
US-5268375-A Dinitrogen heterocyclic derivatives N-substituted by a biphenylmethyl group, and the pharmaceutical compositions in which they are present ELF SANOFI (FR) 1993-12-07 US disclosed
EP-0189326-A2 Derivatives of arginine vasopressin antagonists Medical College of Ohio (US) 1986-07-30 EP disclosed
EP-0061356-B1 ANTAGONISTS OF THE ANTIDIURETIC AND/OR VASOPRESSOR ACTION OF ARGININE VASOPRESSIN Medical College of Ohio (US) 1985-07-17 EP disclosed
EP-0061356-A2 Antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin Medical College of Ohio (US) 1982-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 CYP1A2 1198/4885CYP2C19 658/4885MAPT 2476/4885
US-20020038034-A1 Intermediates for the preparation of 2-imidazolin-5-ones ERG28, CYP51A1, CYP3A5 CYP1A2 32/4885CYP2C19 237/4885MAPT 3696/4885
US-10344019-B2 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 CYP1A2 3826/4885CYP2C19 3298/4885MAPT 2923/4885
US-20250011333-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 CYP1A2 1198/4885CYP2C19 658/4885MAPT 2476/4885
US-11814444-B2 Cyclic polypeptides for PCSK9 inhibition PCSK9, LDLR, PCSK7 CYP1A2 4606/4885CYP2C19 2639/4885MAPT 3313/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 CYP1A2 3826/4885CYP2C19 3298/4885MAPT 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.